Products in pipeline

reMYND's pre-clinical pipeline of small molecules consists primarily of:

• 4 disease-modifying programs for treating Alzheimer's disease (counteracting tau-toxicity)
• 2 programs for treating Parkinson's disease (counteracting α-synuclein toxicity)
• 2 programs for Diabetes mellitus type II (counteracting IAPP-toxicity)

For further information, please contact pipeline@remynd.com.